CERTIFICATE OF EXPRESS MAIL

NUMBER EL 831792540 US

DATE OF DEPOSIT October 9, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: MS Patent Application, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Paula A. Linkhart

Signature

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Eugeen VANMECHELEN
Hugo VANDERSTICHELE

Serial No.: To be assigned

Filed: Herewith
For: DIAGNOSIS OF TAUOPATHIES

Group Art Unit: To be assigned

Examiner: To be assigned

Atty. Dkt. No.: 11362.0016.DVUS01
(INNS016--1)

PRELIMINARY REMARKS

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria VA, 22313-1450

Sir:

This paper provides Applicant's Preliminary Remarks in the above captioned application, which is filed concurrently herewith.

Pursuant to the provisions of 37 C.F.R. §§ 1.51, 1.53, and 1.63 (d) the enclosed Specification has been modified with reference to the original document filed as application number 09/769,180 indicated below (unless otherwise indicate all page numbering below refers to the original 09/769,180 application). Applicant believes that no new matter has been entered by these modifications.

A. At page 1, line 2, following the title, the following was inserted:

--This is a divisional of co-pending application Serial No. 09/769,180, filed 24 January 2001, which claims priority to EP 00870008.0, filed 24 January 2000; United States provisional application SN 60/178,391, filed 27 January 2000; and EP 00870280.5, filed 22 November 2000.--

B. At page 3, line 1, the heading "**AIMS OF THE INVENTION**" was deleted.

C. At page 3, line 1, please the following was inserted:

--SUMMARY OF THE INVENTION

The present invention relates to a method for the diagnosis of a tauopathy in an individual, said method involving:

- determining the ratio of phospho-tau (181)/total tau in said individual;
- inferring that said individual is suffering a tauopathy by comparing the obtained ratio of phospho-tau (181)/total tau in said individual with the ratio of phospho-tau (181)/total tau in control individuals, whereby an altered ratio of phospho-tau (181)/total tau compared to said ratio in control individuals being an indication of tauopathy.

The present invention also relates to a method for the differential diagnosis of a tauopathy versus a non-tauopathy in an individual, said method involving:

- determining the ratio of phospho-tau (181)/total tau in said individual;
- inferring that said individual is suffering a tauopathy by comparing the obtained ratio of phospho-tau (181)/total tau in said individual with the ratio of phospho-tau (181)/total tau in individuals suffering a non-tauopathy or with the phospho-tau (181)/total tau ratio in control individuals, whereby an altered ratio of phospho-tau (181)/total tau compared to said ratio in individuals suffering a non-tauopathy or in control individuals being an indication of tauopathy.--

D. At page 4, line 1, the heading "FIGURE LEGENDS" was deleted and the heading --**BRIEF DESCRIPTION OF THE FIGURES**-- was inserted in its place.

E. After page 38, the original Sequence Listing was deleted and replaced with the current Sequence Listing.

Applicant notes that the Specification filed herewith is modified with respect to the specification originally filed in patent application number 09/769,180 in order to reference the parent and priority applications, to conform to United States preferred headings in the specification, and to supply a Summary of the Invention.

The two paragraphs added in the Summary of the Invention find support in the original Specification at page 9, lines 3-21.

The current claims, 1–20, find support in the original Specification at page 11, line 22 through page 15 and in claims 9 and 10 (this corresponds to page 12, line 18, through page 16, line 28 of the current Specification).

Also transmitted herewith is a diskette containing.the computer readable form of those sequences in the specification, and a verified statement in accordance with the sequence rules.

It is believed that no additional fee is due; however, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Deposit Account No. 01-2508/**11362.0016.DVUS01**.

Applicant respectfully submits that the claims are in proper form and condition for allowance. Applicant requests that the claims be allowed and the application advanced to issue.

The Examiner is invited to contact the undersigned Patent Agent at (713) 787-1589 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

Matthew L. Madsen
Reg. No. 45,594
Patent Agent for Assignee
INNOGENETICS N.V.

HOWREY SIMON ARNOLD & WHITE, LLP
750 Bering Drive
Houston, Texas 77057-2198
(713) 787-1400

Date: October 9, 2003